Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group
- PMID: 2898536
Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group
Abstract
Randomized trials of the Gastrointestinal Tumor Study Group have previously demonstrated enhanced survival of patients with locally unresectable pancreatic cancer treated with 5-fluorouracil in combination with radiation therapy compared with that of patients treated with radiation therapy alone. The present study compared the survival of patients treated with multidrug chemotherapy [streptozocin, mitomycin, and 5-fluorouracil (SMF)] versus radiation combined with 5-fluorouracil followed by the same three-drug SMF combination. In 43 patients randomly allocated between these two arms, an improved median survival for the combined-modality therapy (42 weeks) compared with chemotherapy alone (32 weeks) was demonstrated. Overall survival following this combined-modality treatment program (41% at 1 year) was significantly superior to that following SMF chemotherapy alone (19% at 1 year), by a two-tailed log rank test (P less than .02). Serial studies of the Gastrointestinal Tumor Study Group with patients with locally unresectable pancreatic adenocarcinoma have shown that combined-modality therapy is superior to either optimal radiotherapy or chemotherapy alone.
Similar articles
-
An organized multi-institutional interdisciplinary evaluation of role of radiation therapy alone or combined with chemotherapy in treatment of adenocarcinoma of the gastrointestinal tract.NCI Monogr. 1988;(6):253-7. NCI Monogr. 1988. PMID: 3281030 Clinical Trial.
-
Radiation and chemotherapy. Treatment of localized pancreatic carcinoma.J Fla Med Assoc. 1994 Jun;81(6):403-7. J Fla Med Assoc. 1994. PMID: 8064281 Clinical Trial.
-
Current approaches to multimodality management of advanced pancreatic cancer.Hepatogastroenterology. 1993 Oct;40(5):433-42. Hepatogastroenterology. 1993. PMID: 8270232 Review.
-
Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study.Am J Clin Oncol. 2003 Dec;26(6):543-9. doi: 10.1097/01.coc.0000037143.60502.54. Am J Clin Oncol. 2003. PMID: 14663369 Clinical Trial.
-
[Combination radiotherapy and chemotherapy in cancer of the pancreas. Review of the literature and prospects].Bull Cancer. 1990;77(3):275-81. Bull Cancer. 1990. PMID: 2187546 Review. French.
Cited by
-
Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer.Front Oncol. 2021 Apr 20;11:662205. doi: 10.3389/fonc.2021.662205. eCollection 2021. Front Oncol. 2021. PMID: 33959509 Free PMC article.
-
Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer.Clin Exp Gastroenterol. 2024 Jul 16;17:213-225. doi: 10.2147/CEG.S341189. eCollection 2024. Clin Exp Gastroenterol. 2024. PMID: 39050120 Free PMC article. Review.
-
Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.Radiat Oncol. 2013 Mar 1;8:44. doi: 10.1186/1748-717X-8-44. Radiat Oncol. 2013. PMID: 23452509 Free PMC article. Clinical Trial.
-
A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.Br J Cancer. 2002 May 20;86(10):1551-4. doi: 10.1038/sj.bjc.6600256. Br J Cancer. 2002. PMID: 12085203 Free PMC article. Clinical Trial.
-
Influence of dose-averaged linear energy transfer on tumour control after carbon-ion radiation therapy for pancreatic cancer.Clin Transl Radiat Oncol. 2019 Nov 27;21:19-24. doi: 10.1016/j.ctro.2019.11.002. eCollection 2020 Mar. Clin Transl Radiat Oncol. 2019. PMID: 31886424 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical